Bone Biologics Corporation (BBLG)

NASDAQ: BBLG · IEX Real-Time Price · USD
4.52
-1.48 (-24.67%)
Dec 29, 2023, 4:00 PM EST - Market closed
-24.67%
Market Cap 2.43M
Revenue (ttm) n/a
Net Income (ttm) -6.51M
Shares Out 538.44K
EPS (ttm) -49.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 337,181
Open 5.01
Previous Close 6.00
Day's Range 4.48 - 5.22
52-Week Range 2.91 - 96.00
Beta 0.51
Analysts Strong Buy
Price Target 67.50 (+1,393.36%)
Earnings Date Nov 14, 2023

About BBLG

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2004
Employees 2
Stock Exchange NASDAQ
Ticker Symbol BBLG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for BBLG stock is "Strong Buy" and the 12-month stock price forecast is $67.5.

Price Target
$67.5
(1,393.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Bone Biologics Announces 1-for-8 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

13 days ago - Business Wire

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced r...

5 weeks ago - Business Wire

Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agr...

6 weeks ago - Business Wire

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiative...

3 months ago - Business Wire

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FRESVTGNYTEN
6 months ago - Benzinga

Bone Biologics stock plummets more than 50% after stock offering prices at deep discount

Shares of Bone Biologics Corp. BBLG plummeted 51.9% toward a record low in premarket trading Thursday, after the developer of regenerative medicine for bones announced the pricing of its relatively la...

7 months ago - Market Watch

Bone Biologics Prices $5.0 Million Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the p...

7 months ago - Business Wire

Bone Biologics Effects 1-for-30 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effe...

7 months ago - Business Wire

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC)...

9 months ago - Business Wire

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract researc...

1 year ago - Business Wire

Bone Biologics CEO Issues Letter to Stockholders

BURLINGTON, Mass.

1 year ago - Business Wire

WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

JERSEY CITY, N.J. , Oct. 13, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services announced yesterday the closing of Bone Biologics ...

1 year ago - PRNewsWire

CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Reissuing release to remove "million" after "$5,100,000" in the headline and first sentence of the text. The updated release reads: BONE BIOLOGICS PRICES $5,100,000...

1 year ago - Business Wire

WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering

JERSEY CITY, N.J. , Oct. 7, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics Corporation (N...

1 year ago - PRNewsWire

Bone Biologics Prices $5,100,000 Million Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering ...

1 year ago - Business Wire

Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company's presi...

1 year ago - Business Wire

Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF...

1 year ago - Business Wire

Why Are Bone Biologics Shares Surging On Monday?

Newly listed Bone Biologics Corporation (NASDAQ: BBLG) shares are surging after the Company announced to present at the H.C. Wainwright BioConnect Virtual Conference.

2 years ago - Benzinga

Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company's presi...

2 years ago - Business Wire

Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #BoneBiologics--Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, to...

2 years ago - Business Wire

WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering

JERSEY CITY, N.J., Oct. 15, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of an underwritten public...

2 years ago - PRNewsWire

WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market

JERSEY CITY, N.J., Oct. 13, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the pricing of an underwritten public of...

2 years ago - PRNewsWire

Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #BoneBiologics--Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, to...

2 years ago - Business Wire